Reserchers

KOIZUMI Keiichi Professor

KOIZUMI Keiichi

AffiliationLaboratory of Drug Discovery and Development for Pre-disease, Division of Presymptomatic Disease, Department of Research and Development / Department of Academia-Industry-Government Collaboration

Research fieldsKampo medicines ・Biopharmaceutics・Pre-disease research

Campus careerPh.D.

Biography Academic Research Staff

Education

MAR.1995 B.S. Faculty of Pharmaceutical Sciences, Showa Pharmaceutical University
MAR.1997 M.S. Faculty of Pharmaceutical Sciences, Showa Pharmaceutical University
MAR.2000 Ph.D. Graduate School of Pharmaceutical Sciences, Osaka University

Job career

AUG.2000 Postdoctoral fellow, National Institutes of Health (NIH), USA
APR.2001 Assistant Professor, Division of Pathogenic Biochemistry, Department of Bioscience, Research Institute of WAKAN-YAKU, Toyama Medical and Pharmaceutical University
OCT.2010 Associate Professor, Department of Kampo Diagnostics, Institute of Natural Medicine, University of Toyama
DEC.2020 Professor, Division of Presymptomatic Disease, Institute of Natural Medicine, University of Toyama

Research theme

Department

Division

Section

Outline of the research

The best medicine is that of treatments of the pre-disease state; this is known as mibyou in traditional Japanese medicine. The concept was first explained in the Yellow Emperor’s Inner Canon, the oldest surviving book on Chinese medicine. Recently, many exceptionally effective but expensive pharmaceuticals, such as antibody drugs and molecular-targeted agents, have been developed, and these contribute our health and welfare. However, the increasing burden of treatments using these drugs will surely lead to medical economic disaster. With this in mind, the goal of my study is to clear the biological mechanisms of the pre-disease state and create new preemptive medicines targeting the pre-disease state. I mainly plan to do this using research techniques related to pharmaceutical science, immunology, pharmacology, and traditional medicine.

Thoughts on research

2000 years has been passed from Yellow Emperor’s Inner Canon.
It’s high time to start developing new preemptive medicine for the pre-disease state, Mibyou!
The development will open the door which connect to novel medical and pharmaceutical science.
I strongly believe that the fusion between Herbal medicine and Food science are key role of the success for novel medical pharmaceutical science.

Paper

Koizumi K*., Oku M., Hayashi S., Inujima A., Shibahara N., Chen L., Igarashi Y., Tobe K., Saito S., Kadowaki M., Aihara K.: Identifying pre-disease signals before metabolic syndrome in mice by dynamical network biomarkers. Sci Rep., 24:8767, 2019.

Matsuo K., Koizumi K.*, Fujita M., Morikawa T., Jo M., Shibahara N., Saiki I., Yoshie O., Nakayama T.: Efficient Use of a Crude Drug/Herb Library Reveals Ephedra Herb As a Specific Antagonist for TH2-Specific Chemokine Receptors CCR3, CCR4, and CCR8. Front Cell Dev Biol., 7:54, 2016.

Koizumi K*., Saitoh, Y., Minami T., Tsuneyama K., Miyahara T., Nakayama T., Sakurai H., Takano Y., Nishimura M., Imai T., Yoshie O., Saiki I.: Role of CX3CL1/fractalkine in osteoclast differentiation and bone resorption. J. Immunol., 183: 7825-7831, 2009.

Hojo S., Koizumi K*., Tsuneyama K., Arita Y., Cui Z., Shinohara K., Minami T., Hashimoto I., Nakayama T., Sakurai H., Takano Y., Yoshie O., Tsukada K., Saiki I.: High level expression of chemokine CXCL16 by tumor cells correlated with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res., 67: 4725-4731, 2007.

Koizumi K*., Hojo S., Akashi T., Yasumoto K., Saiki I.:Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci., 98:1652-1658, 2007.

keyword

Pre-disease (so-called Mibyou in traditional Japanese medicine)、Nanosome、BiND、Kampo、Pharmaceutical formulation